TABLE 1.
Baseline characteristics of patientsa
| Characteristic | All patients (n = 77) |
|---|---|
| Demographics | |
| Age (yrs) | 53.0 (22.0–64.7) |
| Male (%) | 41 (53.2) |
| Weight (kg) | 64.0 (48.9–84.3) |
| Underlying hematological diseases | |
| Acute myeloid leukemia | 35 |
| Acute lymphoblastic leukemia | 16 |
| Myelodysplastic syndrome | 11 |
| Lymphoma | 8 |
| Chronic myeloid leukemia | 1 |
| Chronic lymphoblastic leukemia | 1 |
| Othersb | 5 |
| Longitudinal follow-up of POS treatment | |
| Duration of follow-up (days) | 84 (41–376) |
| No. of dose adjustments/patient | 1 (0–2) |
| No. of POS Cmin/patient | 9 (4–18) |
a
Data are indicated as numbers (%) or median (25th–75th percentiles).
b
Others include one idiopathic medullary aplasia, two nondifferentiated acute leukemia, and two acute biclonal leukemia.